Age-dependent changes in the putamen transcriptome and proteome of a transgenic minipig model of Huntington's disease
Huntington's disease is an inherited neurodegenerative disorder with no disease-modifying treatment available. Preclinical trials of gene therapies rely on large animal models and the transgenic Huntington's disease (TgHD) minipig is one of them. Minipigs live more than a decade, so the effect of a single dose of gene therapy can be followed for years. The TgHD transgene carries a mixed CAG/CAA repeat that is not expected to expand somatically. However, its putamen, part of the striatum that degenerates first in patients, had not been examined by genome-wide methods, nor beyond 4 years of age. We compared the putamen of transgenic and wild-type minipigs at 4 and 8 years by RNA sequencing and label-free mass spectrometry proteomics, and measured mutant huntingtin by immunoassay. Seven genes were differentially expressed at 4 years and 3,324 at 8 years, and the pathway changes of the transcriptome and the proteome were concordant at that age. The D2 medium spiny neuron marker gene set was reduced at 8 years in both the transcriptome and the proteome. Mitochondrial and oxidative phosphorylation pathways were positively enriched at 4 years and negatively enriched at 8 years. Immune and complement pathways were positively enriched at 8 years, and the number of altered splicing events increased almost fivefold between 4 and 8 years. We detected no age-dependent accumulation of soluble mutant huntingtin. Since the repeat does not expand, these changes developed without somatic expansion, a major driver of progression in human Huntington's disease. We propose that the reduced neuronal markers reflect a loss of neuronal identity rather than neuronal death. The TgHD minipig would then recapitulate the slow early phase of the disease, when treatment is arguably most likely to help.
Authors
- Petr Vodička (ORCID: https://orcid.org/0000-0002-9381-3646)
- Jiřı́ Klı́ma (ORCID: https://orcid.org/0000-0001-6915-7522)
- Ivona Valeková (ORCID: https://orcid.org/0000-0001-5587-0597)
- Jana Juhásová (ORCID: https://orcid.org/0000-0001-7022-6812)
- Eva Kamenná (ORCID: https://orcid.org/0000-0003-1023-1403)
- Georgina F Osborne (ORCID: https://orcid.org/0000-0001-8308-3179)
- Dávid Sekáč (ORCID: https://orcid.org/0009-0005-6546-0221)
- Jakub Červenka (ORCID: https://orcid.org/0000-0002-9947-2045)
- Zdeňka Ellederová (ORCID: https://orcid.org/0000-0001-6695-6345)
- Christian Landles (ORCID: https://orcid.org/0000-0001-9715-6447)
- Helena Kupcová Skalníková (ORCID: https://orcid.org/0000-0003-0591-5018)
- Štefan Juhás (ORCID: https://orcid.org/0000-0002-2866-0727)
- Jiří Klempíř (ORCID: https://orcid.org/0000-0002-0735-7155)
- Kateryna Nemesh (ORCID: https://orcid.org/0009-0009-7853-1630)
- Jan Motlík (ORCID: https://orcid.org/0000-0003-4194-8431)
- Kolesnikova Anastasiia
Institutions
- Czech Academy of Sciences (CZ)
- Charles University (CZ)
- Czech Academy of Sciences, Institute of Animal Physiology and Genetics (CZ)
- Institute of Animal Physiology of the Slovak Academy of Sciences (SK)
- University College London (GB)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-16
- DOI
- https://doi.org/10.64898/2026.11.13.766462
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- preprint
Funders
- CHDI Foundation
- European Federation of Pharmaceutical Industries and Associations
- University College London
- European Commission
- Ministerstvo Zdravotnictví Ceské Republiky
- Akademie Věd České Republiky
- HORIZON EUROPE Framework Programme